Charleston Laboratories, Inc. Announces Presentations at the Annual Scientific Meeting of the American Pain Society

The second presentation is entitled "Efficacy of CL-108 compared to hydrocodone 7.5 mg/acetaminophen 325 mg in preventing vomiting and the use of anti-emetics, Opioid-Induced Nausea and Vomiting (OINV)."

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research and development of novel pain products to prevent the burdensome side effects related to opioid analgesics and other products.  The Company has a strategic collaboration with Daiichi Sankyo, Inc. for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone products, including CL-108, which is being studied for the treatment of moderate to severe pain while preventing or reducing Opioid-Induced Nausea and Vomiting (OINV).

Charleston's product pipeline currently seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to enter into other discovery and commercialization alliances with partners motivated to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

Logo - http://photos.prnewswire.com/prnh/20140909/144224

SOURCE Charleston Laboratories, Inc.

Related Links

http://www.charlestonlabs.com